{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:04Z","timestamp":1789593724574,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06378-y","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T23:29:53Z","timestamp":1745537393000},"page":"2495-2505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Whole brain radiotherapy combined with CART-cell therapy for relapsed\/refractory central nervous system B-cell lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Hui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuenan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"3","key":"6378_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/neuonc\/noy192","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT (2019) Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 21(3):296\u2013305","journal-title":"Neuro Oncol"},{"issue":"7","key":"6378_CR2","first-page":"e1512","volume":"9","author":"EC Burton","year":"2017","unstructured":"Burton EC, Ugiliweneza B, Kolikonda MK et al (2017) A regional multicenter retrospective analysis of patients with primary central nervous system lymphoma diagnosed from 2000\u20132012: treatment patterns and clinical outcomes. Cureus 9(7):e1512","journal-title":"Cureus"},{"issue":"5","key":"6378_CR3","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217\u2013e227","journal-title":"Lancet Haematol"},{"issue":"2","key":"6378_CR4","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","volume":"8","author":"AJM Ferreri","year":"2021","unstructured":"Ferreri AJM, Doorduijn JK, Re A et al (2021) MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol 8(2):e110\u2013e121","journal-title":"Lancet Haematol"},{"issue":"1","key":"6378_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K et al (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9(1):29","journal-title":"Nat Rev Dis Primers"},{"key":"6378_CR6","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2023) Correction: the 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720\u20131748. Leukemia 37(9):1944\u201351"},{"issue":"6","key":"6378_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/cns.15.34","volume":"4","author":"P Ambady","year":"2015","unstructured":"Ambady P, Holdhoff M, Bonekamp D, Wong F, Grossman SA (2015) Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncol 4(6):393\u2013398","journal-title":"CNS Oncol"},{"issue":"14","key":"6378_CR8","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","volume":"122","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P (2013) How I treat CNS lymphomas. Blood 122(14):2318\u20132330","journal-title":"Blood"},{"issue":"11","key":"6378_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3324\/haematol.2011.060434","volume":"97","author":"C Soussain","year":"2012","unstructured":"Soussain C, Choquet S, Fourme E et al (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 97(11):1751\u20131756","journal-title":"Haematologica"},{"issue":"9","key":"6378_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1586\/14737140.2013.829634","volume":"13","author":"S Dahiya","year":"2013","unstructured":"Dahiya S, Murphy ES, Chao ST, Stevens GH, Peereboom DM, Ahluwalia MS (2013) Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. Expert Rev Anticancer Ther 13(9):1109\u20131119","journal-title":"Expert Rev Anticancer Ther"},{"issue":"21","key":"6378_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1182\/blood.2023020168","volume":"142","author":"JP Alderuccio","year":"2023","unstructured":"Alderuccio JP, Nayak L, Cwynarski K (2023) How I treat secondary CNS involvement by aggressive lymphomas. Blood 142(21):1771\u20131783","journal-title":"Blood"},{"key":"6378_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","volume":"93","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Cheah CY, Bendtsen MD et al (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57\u201368","journal-title":"Eur J Cancer"},{"issue":"17","key":"6378_CR13","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","volume":"10","author":"SR Plotkin","year":"2004","unstructured":"Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10(17):5643\u20135646","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6378_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jocn.2012.04.001","volume":"19","author":"SF Wong","year":"2012","unstructured":"Wong SF, Gan HK, Cher L (2012) A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide. J Clin Neurosci 19(11):1501\u20131505","journal-title":"J Clin Neurosci"},{"issue":"4","key":"6378_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdq548","volume":"22","author":"NB Khimani","year":"2011","unstructured":"Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM (2011) Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol 22(4):979\u2013984","journal-title":"Ann Oncol"},{"issue":"3","key":"6378_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","volume":"84","author":"C Houillier","year":"2015","unstructured":"Houillier C, Choquet S, Touitou V et al (2015) Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology 84(3):325\u2013326","journal-title":"Neurology"},{"key":"6378_CR17","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X et al (2022) Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol 12:901797","journal-title":"Front Oncol"},{"issue":"5","key":"6378_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000537995","volume":"147","author":"Z Lin","year":"2024","unstructured":"Lin Z, Ma J, Ma Y et al (2024) Zanubrutinib plus cytarabine in patients with refractory\/relapsed primary central nervous system lymphoma. Acta Haematol 147(5):555\u2013563","journal-title":"Acta Haematol"},{"issue":"23","key":"6378_CR19","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A et al (2017) PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood 129(23):3071\u20133073","journal-title":"Blood"},{"issue":"2","key":"6378_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-021-03909-1","volume":"156","author":"N Kim","year":"2022","unstructured":"Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS (2022) Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. J Neurooncol 156(2):307\u2013316","journal-title":"J Neurooncol"},{"issue":"11","key":"6378_CR21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","volume":"69","author":"AF Hottinger","year":"2007","unstructured":"Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69(11):1178\u20131182","journal-title":"Neurology"},{"issue":"1","key":"6378_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN et al (2023) Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol 16(1):111","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6378_CR23","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","volume":"108","author":"C Lacan","year":"2023","unstructured":"Lacan C, Caron J, Tarantino N et al (2023) CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes. Haematologica 108(12):3485\u20133490","journal-title":"Haematologica"},{"issue":"7","key":"6378_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N et al (2024) CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol 99(7):1240\u20131249","journal-title":"Am J Hematol"},{"issue":"8","key":"6378_CR25","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ajh.27354","volume":"99","author":"A Alsouqi","year":"2024","unstructured":"Alsouqi A, Ahmed G, Wang J et al (2024) Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol 99(8):1624\u20131627","journal-title":"Am J Hematol"},{"issue":"3","key":"6378_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bjh.19569","volume":"205","author":"N Epperla","year":"2024","unstructured":"Epperla N, Hashmi H, Ahn KW et al (2024) Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. Br J Haematol 205(3):1202\u20131207","journal-title":"Br J Haematol"},{"key":"6378_CR27","doi-asserted-by":"crossref","unstructured":"Anna Ossami Saidy,Christophe Peczynski, Eva Michel, Jacques-Emmanuel Galimard, Herv\u00e9 Finel, Ariane Boumendil, Michael Daskalakis, Urban Novak, David Beauvais, J\u00fcrgen Finke, Peter Vandenberghe, Nicolaus Kr\u00f6ger et al (2024) Efficacy and toxicity of anti-CD19 CAR T-cells in patients with primary and secondary CNS-lymphoma \u2013 an analysis of the lymphoma working party of the EBMT and the GOCART coalition. Abstract presented at: 2024 EHA Annual Congress 13\u201316","DOI":"10.1182\/blood-2023-174883"},{"issue":"19","key":"6378_CR28","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","volume":"8","author":"GY Cederquist","year":"2024","unstructured":"Cederquist GY, Schefflein J, Devlin SM et al (2024) CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv 8(19):5192\u20135199","journal-title":"Blood Adv"},{"issue":"1","key":"6378_CR29","doi-asserted-by":"publisher","first-page":"e3243","DOI":"10.1002\/hon.3243","volume":"42","author":"HS Ababneh","year":"2024","unstructured":"Ababneh HS, Frigault MJ, Ng AK, Patel CG (2024) Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy. Hematol Oncol 42(1):e3243","journal-title":"Hematol Oncol"},{"key":"6378_CR30","doi-asserted-by":"publisher","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2021","unstructured":"Qin VM, Haynes NM, D\u2019Souza C, Neeson PJ, Zhu JJ (2021) CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol 12:813832","journal-title":"Front Immunol"},{"issue":"8","key":"6378_CR31","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S1470-2045(19)30461-9","volume":"20","author":"I Minn","year":"2019","unstructured":"Minn I, Rowe SP, Pomper MG (2019) Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol 20(8):e443\u2013e451","journal-title":"Lancet Oncol"},{"issue":"5","key":"6378_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, Zuo S, Deng B et al (2020) Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood 135(5):387\u2013391","journal-title":"Blood"},{"issue":"1","key":"6378_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u20132","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"6378_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"6378_CR35","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s11912-024-01609-3","volume":"26","author":"C Houillier","year":"2024","unstructured":"Houillier C, Choquet S (2024) CAR T-cell therapy for central nervous system lymphoma. Curr Oncol Rep 26(11):1521\u20131529","journal-title":"Curr Oncol Rep"},{"key":"6378_CR36","doi-asserted-by":"publisher","first-page":"2900310","DOI":"10.1155\/2022\/2900310","volume":"2022","author":"F Xue","year":"2022","unstructured":"Xue F, Zheng P, Liu R et al (2022) The autologous hematopoietic stem cells transplantation combination-based chimeric antigen receptor T-cell therapy improves outcomes of relapsed\/refractory central nervous system B-cell lymphoma. J Oncol 2022:2900310","journal-title":"J Oncol"},{"issue":"9","key":"6378_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/jpm13091399","volume":"13","author":"I Kobzeva","year":"2023","unstructured":"Kobzeva I, Astrelina T, Suchkova Y et al (2023) Effect of radiation therapy on composition of lymphocyte populations in patients with primary breast cancer. J Pers Med 13(9):1399","journal-title":"J Pers Med"},{"key":"6378_CR38","doi-asserted-by":"publisher","first-page":"648655","DOI":"10.3389\/fonc.2021.648655","volume":"11","author":"PQ Fang","year":"2021","unstructured":"Fang PQ, Gunther JR, Wu SY et al (2021) Radiation and CAR T-cell therapy in lymphoma: future frontiers and potential opportunities for synergy. Front Oncol 11:648655","journal-title":"Front Oncol"},{"issue":"16","key":"6378_CR39","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/bloodadvances.2022007011","volume":"6","author":"P Lesueur","year":"2022","unstructured":"Lesueur P, Damaj G, Hoang-Xuan K et al (2022) Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv 6(16):4807\u20134815","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06378-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:13:46Z","timestamp":1746400426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06378-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6378"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06378-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board. The study was approved by the Ethics Committee at the Beijing Gobroad Hospital in Beijing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"I have not used any materials from other sources that require permission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The Registration No. of the study\/trial: ChiCTR2200058972.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}